On February 16, 2022, FDA posted a compounding danger notify describing the opportunity dangers connected with at-residence use of compounded ketamine nasal spray and a number of other adverse function stories. The February 2022 compounding hazard warn also supplied details about Spravato, that is subject matter to a Danger Evaluation and Mitigatio